Hereditary Angioedema Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | KalVista Pharma, Intellia Therapeutics, BioMarin Pharma

Posted on
by

Hereditary Angioedema Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | KalVista Pharma, Intellia Therapeutics, BioMarin Pharma
“Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the 7MM.

DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Hereditary Angioedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Angioedema Market Forecast

 

Some of the key facts of the Hereditary Angioedema Market Report: 

  • The Hereditary Angioedema market size was valued approximately USD 2,300 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • 13,900 diagnosed prevalent cases of Hereditary Angioedema were reported in the 7MM in 2022; this number is predicted to rise at a significant CAGR by 2032.
  • With around 1,400 cases, the UK had the highest diagnosed prevalence of Hereditary Angioedema among European nations in 2022. Germany came in second with 1,300 instances. However, with less than a thousand cases each in 2022, Spain and Italy had the lowest rates of diagnosed prevalent population.
  • Type I, Type II, and Hereditary Angioedema with normal C1-INH (Type III) are the three categories for type-specific diagnosed prevalent instances of Hereditary Angioedema. Of them, Type I Hereditary Angioedema was responsible for the greatest number of cases in the 7MM in 2022.
  • Due to the country’s declining population, Japan’s estimated 460 diagnosed prevalent cases of Hereditary Angioedema in 2022 are predicted to diminish marginally by 2032 at a respectable CAGR.
  • Potential therapeutic targets include blocking the bradykinin-B2-receptor, plasma kallikrein inhibitor, inhibiting factor XII (for example, by using a blocking antibody), and preventing the cleavage of prekallikrein. In addition, a small number of gene treatments are being developed to treat Hereditary Angioedema; they will aid in the treatment of recently discovered mutations such FXII and PLG HAE.
  • Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
  • Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
  • The Hereditary Angioedema epidemiology based on gender analyzed that the diagnosed prevalent cases of Hereditary Angioedema in the 7MM varied according to gender, with prevalent cases higher in females than males
  • The Hereditary Angioedema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics.

 

Hereditary Angioedema Overview

Rarely occurring hereditary angioedema (HAE) is characterized by recurrent episodes of localized subcutaneous (SC) or mucosal edema, most commonly affecting the oropharynx, upper respiratory tract, skin, and intestines.

 

Get a Free sample for the Hereditary Angioedema Market Report:

https://www.delveinsight.com/report-store/hereditary-angioedema-market

 

Hereditary Angioedema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Hereditary Angioedema Epidemiology Segmentation:

The Hereditary Angioedema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Hereditary Angioedema
  • Prevalent Cases of Hereditary Angioedema by severity
  • Gender-specific Prevalence of Hereditary Angioedema
  • Diagnosed Cases of Episodic and Chronic Hereditary Angioedema

 

Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Epidemiology Forecast

 

Hereditary Angioedema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched during the study period. The analysis covers Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hereditary Angioedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Hereditary Angioedema Therapies and Key Companies

  • KVD900: KalVista Pharmaceuticals
  • NTLA-2002: Intellia Therapeutics
  • BMN 331: BioMarin Pharmaceutical
  • Garadacimab: CSL Behring
  • Donidalorse: Ionis Pharmaceuticals
  • STAR-0215: Astria Therapeutics
  • PHA121: Pharvaris Netherlands B.V
  • NTLA-2002: Intellia Therapeutics
  • TAK-743: Takeda
  • KVD900: KalVista Pharmaceuticals
  • CSL312: CSL Behring
  • Lanadelumab: Shire

 

Discover more about therapies set to grab major Hereditary Angioedema market share @ Hereditary Angioedema Treatment Market

 

Hereditary Angioedema Market Strengths

  • Increasing identification of a novel genetic mutation in various regions warranting further focus on the types and associated pathophysiology, including recognition of hormonal changes

 

Hereditary Angioedema Market Opportunities

  • Proliferating demand for therapies with improved patient compliance, fewer side effects, improved resistance profile, and long-acting therapies

 

Scope of the Hereditary Angioedema Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
  • Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
  • Hereditary Angioedema Therapeutic Assessment: Hereditary Angioedema current marketed and Hereditary Angioedema emerging therapies
  • Hereditary Angioedema Market Dynamics: Hereditary Angioedema market drivers and Hereditary Angioedema market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Hereditary Angioedema Unmet Needs, KOL’s views, Analyst’s views, Hereditary Angioedema Market Access and Reimbursement 

 

To know more about Hereditary Angioedema companies working in the treatment market, visit @ Hereditary Angioedema Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Hereditary Angioedema Market Report Introduction

2. Executive Summary for Hereditary Angioedema

3. SWOT analysis of Hereditary Angioedema

4. Hereditary Angioedema Patient Share (%) Overview at a Glance

5. Hereditary Angioedema Market Overview at a Glance

6. Hereditary Angioedema Disease Background and Overview

7. Hereditary Angioedema Epidemiology and Patient Population

8. Country-Specific Patient Population of Hereditary Angioedema 

9. Hereditary Angioedema Current Treatment and Medical Practices

10. Hereditary Angioedema Unmet Needs

11. Hereditary Angioedema Emerging Therapies

12. Hereditary Angioedema Market Outlook

13. Country-Wise Hereditary Angioedema Market Analysis (2019–2032)

14. Hereditary Angioedema Market Access and Reimbursement of Therapies

15. Hereditary Angioedema Market Drivers

16. Hereditary Angioedema Market Barriers

17.  Hereditary Angioedema Appendix

18. Hereditary Angioedema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/